Compare LTC Properties Inc (LTC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs 10X Genomics Inc — how do they compare? LTC Properties Inc trades at $42.73 (market cap $2.27B), while 10X Genomics Inc trades at $81.27 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 4.4× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.42% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and 10X Genomics Inc for 91 Days on average.
| LTC | TXG | |
|---|---|---|
Market Cap | $2.27B | $10.07B |
Volume | 574,171 | 5,657,286 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $97.74 |
52-Week Low | $33.98 | $11.48 |
Typical Hold Time | 88 Days | 91 Days |
Enterprise Value | $3.01B | $9.59B |
Dividend Yield | 5.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.63, up 1.96% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The REIT maintains strong fundamentals with 38.93% net margins and consistent dividend payments of $0.19 monthly. Recent acquisitions totaling $160 million signal aggressive growth in seniors housing properties, though the stock faces resistance near $43.
Outlook remains cautiously optimistic with a $49.67 analyst price target suggesting 16% upside potential. Key opportunities include demographic tailwinds in senior care and portfolio transformation, while risks involve rising interest rates and execution challenges in SHOP segment expansion. The 31.82% buy rating reflects balanced Wall Street sentiment amid transition phase.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
